Papaverine hydrochloride is a myotropic antispasmodic agent. It inhibits phosphodiesterase, causes accumulation of cyclic 3,5-adenosine monophosphate (AMP) and decrease of calcium in the cell.
Relaxes smooth muscles of internal organs (gastrointestinal tract, respiratory tract, genitourinary system) and blood vessels.
In high doses it reduces excitability of the heart muscle and slows intracardiac conduction.
The action of papaverine on the central nervous system is weak but in high doses it produces a sedative effect.
Bioavailability of papaverine after rectal administration (according to preclinical studies) is about 25%. The binding to plasma proteins is 90%. It is well distributed, penetrates through histohematic barriers.
Metabolized in liver. The elimination half-life (T1/2) is 0.5-2 hours (possibly increased up to 24 hours). It is excreted by kidneys as metabolites.
Colitis, Urolithiasis, Hypertension (high blood pressure), Pain, Bronchospasm, Gallstone disease, Biliary dyskinesia, Colic
- Spasms (severe narrowing of the lumen) of the blood vessels of the brain,
- Endarteritis (inflammation of the inner lining of the arteries,
- cholecystitis (inflammation of the gallbladder,
- spasm.endarteritis (inflammation of the lining of the arteries),
- cholecystitis (inflammation of the gallbladder),
- pylorospasm (spasm of the stomach’s gateway muscles),
- spastic colitis,
- spasm of the urinary tract,
- bronchospasm (narrowing of the lumen of the bronchi).
Composition per suppository:
Papaverine hydrochloride – 20 mg;
How to take, the dosage
Rectally. After releasing the suppository from the contoured package, it is inserted into the anus.
One suppository 2 – 3 times a day after spontaneous bowel emptying or purging enema.
Decreases the effect of dopetite.
The effectiveness decreases with smoking.
With caution and in low doses should be used in elderly and debilitated patients, as well as in patients with craniocerebral trauma, hepatic and renal disorders, hypothyroidism, insufficient adrenal function, prostatic hypertrophy, supraventricular tachycardia and shock.
Alcohol should be avoided during treatment.
Hypersensitivity to the components of the drug, atrioventricular block, glaucoma, severe hepatic insufficiency, advanced age (risk of hyperthermia), childhood, since the dosing regimen in children is not indicated.
With caution and in small doses are used in conditions after craniocerebral injury, chronic renal insufficiency, insufficiency of adrenal function, hypothyroidism, prostatic hyperplasia, supraventricular tachycardia, shock states.
Allergic reactions atrioventricular block ventricular extrasystole increased activity of “hepatic” transaminases decreased blood pressure drowsiness constipation eosinophilia.
Symptoms: diplopia weakness decreased blood pressure drowsiness.
Treatment: symptomatic (maintenance of blood pressure).
Safety of the drug in pregnancy and lactation has not been established. Administration of the drug during pregnancy is possible only by prescription of a physician if the estimated benefits to the mother exceed the potential risk to the fetus and child. Breast-feeding should be suspended during treatment with the drug.
2 years. Do not use the drug after the expiration date stated on the package.
|Conditions of storage|
In a dry, light-protected place at a temperature not exceeding 25 °C
Nizhpharm AO, Russia
Buy Papaverine, rectal 20 mg 10 pcs with delivery to USA, UK, Europe and over 120 other countries.